Interlaboratory reliability of hybrid capture 2

Philip E. Castle, Cosette M. Wheeler, Diane Solomon, Mark Schiffman, Cheri L. Peyton

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

We evaluated the interlaboratory reproducibility of the Hybrid Capture 2 (HC2; Digene, Gaithersburg, MD), a test for oncogenic human papillomavirus (HPV) DNA, using data from 4 clinical center (CC) laboratories and the quality control (QC) laboratory participating in the ASCUS (atypical squamous cells of undetermined significance) and LSIL (low-grade squamous intraepithelial lesion) Triage Study (ALTS). Residual liquid cytology specimens were tested routinely throughout the duration of ALTS at CC laboratories, and a stratified (by time in the study) random sample of specimens was retested by the HPV QC laboratory using equivalent protocols. Of the specimens selected (N = 1,175, 5.50% of all specimens obtained), 1,072 (91.23%) had sufficient specimen volume for retesting. The κ value between all CC laboratories and the HPV QC laboratory was 0.84 (95% confidence interval, 0.78-0.89), with κ values for individual CCs and the HPV QC laboratory ranging from 0.79 to 0.89. Agreement between test results was lowest among results for women with negative cytologic findings (0. 73); among those with equivocal or abnormal cytologic findings, κ values were 0.80 or more. These data show that HC2 is a reliable test for detecting clinically relevant oncogenic HPV DNA.

Original languageEnglish (US)
Pages (from-to)238-245
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume122
Issue number2
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Quality Control
Triage
Human Papillomavirus DNA Tests
Cell Biology
Confidence Intervals
DNA
Squamous Intraepithelial Lesions of the Cervix

Keywords

  • Cervical cancer
  • HPV
  • Human papillomavirus
  • Hybrid Capture 2
  • PCR
  • Polymerase chain reaction
  • Reproducibility

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Interlaboratory reliability of hybrid capture 2. / Castle, Philip E.; Wheeler, Cosette M.; Solomon, Diane; Schiffman, Mark; Peyton, Cheri L.

In: American Journal of Clinical Pathology, Vol. 122, No. 2, 08.2004, p. 238-245.

Research output: Contribution to journalArticle

Castle, PE, Wheeler, CM, Solomon, D, Schiffman, M & Peyton, CL 2004, 'Interlaboratory reliability of hybrid capture 2', American Journal of Clinical Pathology, vol. 122, no. 2, pp. 238-245. https://doi.org/10.1309/BA43-HMCA-J26V-WQH3
Castle, Philip E. ; Wheeler, Cosette M. ; Solomon, Diane ; Schiffman, Mark ; Peyton, Cheri L. / Interlaboratory reliability of hybrid capture 2. In: American Journal of Clinical Pathology. 2004 ; Vol. 122, No. 2. pp. 238-245.
@article{f9fdeadd95f4446383effa854f47e060,
title = "Interlaboratory reliability of hybrid capture 2",
abstract = "We evaluated the interlaboratory reproducibility of the Hybrid Capture 2 (HC2; Digene, Gaithersburg, MD), a test for oncogenic human papillomavirus (HPV) DNA, using data from 4 clinical center (CC) laboratories and the quality control (QC) laboratory participating in the ASCUS (atypical squamous cells of undetermined significance) and LSIL (low-grade squamous intraepithelial lesion) Triage Study (ALTS). Residual liquid cytology specimens were tested routinely throughout the duration of ALTS at CC laboratories, and a stratified (by time in the study) random sample of specimens was retested by the HPV QC laboratory using equivalent protocols. Of the specimens selected (N = 1,175, 5.50{\%} of all specimens obtained), 1,072 (91.23{\%}) had sufficient specimen volume for retesting. The κ value between all CC laboratories and the HPV QC laboratory was 0.84 (95{\%} confidence interval, 0.78-0.89), with κ values for individual CCs and the HPV QC laboratory ranging from 0.79 to 0.89. Agreement between test results was lowest among results for women with negative cytologic findings (0. 73); among those with equivocal or abnormal cytologic findings, κ values were 0.80 or more. These data show that HC2 is a reliable test for detecting clinically relevant oncogenic HPV DNA.",
keywords = "Cervical cancer, HPV, Human papillomavirus, Hybrid Capture 2, PCR, Polymerase chain reaction, Reproducibility",
author = "Castle, {Philip E.} and Wheeler, {Cosette M.} and Diane Solomon and Mark Schiffman and Peyton, {Cheri L.}",
year = "2004",
month = "8",
doi = "10.1309/BA43-HMCA-J26V-WQH3",
language = "English (US)",
volume = "122",
pages = "238--245",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - Interlaboratory reliability of hybrid capture 2

AU - Castle, Philip E.

AU - Wheeler, Cosette M.

AU - Solomon, Diane

AU - Schiffman, Mark

AU - Peyton, Cheri L.

PY - 2004/8

Y1 - 2004/8

N2 - We evaluated the interlaboratory reproducibility of the Hybrid Capture 2 (HC2; Digene, Gaithersburg, MD), a test for oncogenic human papillomavirus (HPV) DNA, using data from 4 clinical center (CC) laboratories and the quality control (QC) laboratory participating in the ASCUS (atypical squamous cells of undetermined significance) and LSIL (low-grade squamous intraepithelial lesion) Triage Study (ALTS). Residual liquid cytology specimens were tested routinely throughout the duration of ALTS at CC laboratories, and a stratified (by time in the study) random sample of specimens was retested by the HPV QC laboratory using equivalent protocols. Of the specimens selected (N = 1,175, 5.50% of all specimens obtained), 1,072 (91.23%) had sufficient specimen volume for retesting. The κ value between all CC laboratories and the HPV QC laboratory was 0.84 (95% confidence interval, 0.78-0.89), with κ values for individual CCs and the HPV QC laboratory ranging from 0.79 to 0.89. Agreement between test results was lowest among results for women with negative cytologic findings (0. 73); among those with equivocal or abnormal cytologic findings, κ values were 0.80 or more. These data show that HC2 is a reliable test for detecting clinically relevant oncogenic HPV DNA.

AB - We evaluated the interlaboratory reproducibility of the Hybrid Capture 2 (HC2; Digene, Gaithersburg, MD), a test for oncogenic human papillomavirus (HPV) DNA, using data from 4 clinical center (CC) laboratories and the quality control (QC) laboratory participating in the ASCUS (atypical squamous cells of undetermined significance) and LSIL (low-grade squamous intraepithelial lesion) Triage Study (ALTS). Residual liquid cytology specimens were tested routinely throughout the duration of ALTS at CC laboratories, and a stratified (by time in the study) random sample of specimens was retested by the HPV QC laboratory using equivalent protocols. Of the specimens selected (N = 1,175, 5.50% of all specimens obtained), 1,072 (91.23%) had sufficient specimen volume for retesting. The κ value between all CC laboratories and the HPV QC laboratory was 0.84 (95% confidence interval, 0.78-0.89), with κ values for individual CCs and the HPV QC laboratory ranging from 0.79 to 0.89. Agreement between test results was lowest among results for women with negative cytologic findings (0. 73); among those with equivocal or abnormal cytologic findings, κ values were 0.80 or more. These data show that HC2 is a reliable test for detecting clinically relevant oncogenic HPV DNA.

KW - Cervical cancer

KW - HPV

KW - Human papillomavirus

KW - Hybrid Capture 2

KW - PCR

KW - Polymerase chain reaction

KW - Reproducibility

UR - http://www.scopus.com/inward/record.url?scp=3242794911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242794911&partnerID=8YFLogxK

U2 - 10.1309/BA43-HMCA-J26V-WQH3

DO - 10.1309/BA43-HMCA-J26V-WQH3

M3 - Article

C2 - 15323141

AN - SCOPUS:3242794911

VL - 122

SP - 238

EP - 245

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -